Information Provided By: 
Fly News Breaks for March 1, 2016
HZNP
Mar 1, 2016 | 07:30 EDT
UBS said Horizon Pharma's Q4 results were another demonstration of strong fundamentals and execution but noted the stock sold off on its disclosure of receiving a subpoena from the U.S. government. UBS believes the company will continue to execute and put up good numbers, leading to a significant move upward for the shares. UBS reiterated its Buy rating and $39 price target on Horizon Pharma shares.
News For HZNP From the Last 2 Days
There are no results for your query HZNP
